Reports Q4 revenue $0.7M, consensus $1.65M. "We are confident that FTX-6058 has the potential to provide a differentiated therapeutic option for people living with sickle cell disease and that the clinical and preclinical data generated to date demonstrate a favorable benefit-risk profile. We are working diligently to address the clinical hold," said Robert J. Gould, Ph.D., Fulcrum’s interim president and chief executive officer. "Additionally, we remain on track to complete enrollment in the losmapimod Phase 3 REACH trial in the second half of 2023, and are excited about potentially being first to market with a treatment for FSHD patients who have no approved therapies."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on FULC:
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022
- Fulcrum Therapeutics downgraded at Morgan Stanley on clinical hold uncertainty
- Fulcrum Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
- Fulcrum Therapeutics price target lowered to $20 from $26 at Oppenheimer
- Fulcrum Therapeutics downgraded to Underperform from Neutral at BofA
